Update on Alzheimer’s disease treatments
2025 brings disappointing news for Alzheimer's patients in Europe: regulatory hurdles for new treatments and major clinical trial failures.
Cell and Gene Therapies: A Perspective
Cell and gene therapies promise medical breakthroughs, but manufacturing complexity, $2M price tags, and patient journey challenges force major pharma exits.
Roche and Alzheimer’s disease
SPECIAL REPORT 25.09
Roche and Alzheimer’s disease
On July 28, at the Alzheimer’s Association International Conference (AAIC) held in Toronto (Canada), Roche presented new data from its development portfolio including additional diagnostics outcomes.
In several oral presentations Roche disclosed its latest results from the ongoing trontinemab’s
Sanofi au plus bas depuis trois ans.
SPECIAL REPORT 25.08
Sanofi au plus bas depuis trois ans.
Chers anciens collègues,
Ancien salarié et dirigeant de Sanofi je reste, comme de nombreux d’entre vous, très attentif à son évolution. Le 31 juillet est à nouveau une journée sombre pour le Groupe puisque le cours de son
Abivax: Ahead of a bright future?
SPECIAL REPORT 25.07
Abivax: Ahead of a bright future?
On Tuesday, July 22, just after the closure of Wall Street, Abivax announced positive phase 3 results for the treatment of ulcerative colitis (UC). The Paris and Boston-based biotechnology company conducted two clinical studies (ABTECT-1 and ABTECT-2 in 8 week
Targeted protein degradation
SPECIAL REPORT 25.5
Scientific publication
This article was published in a different format in the April issue of MedNous
Learn more
The development of new drugs is dependent on many factors, and one of the most important is being able to identify and reach a target. For years, a
The European Commission approves Leqembi®
Scientific publication
This article was published in a different format in the April issue of MedNous
The Alzheimer’s disease drug, Leqembi® (lecanemab), has been approved by the European Commission following extra reviews of the product’s safety. The decision was announced on 16 April by the product’s co-developer